drugset / Trial / NCT04393441

Efficacy and Safety of a New Artificial Tear Formulation Compared With Systane Ultra Multidose in Participants With Dry Eye Disease

NCT04393441

Phase 3 Completed 400 enrolled Allergan
RandomizedParallel-groupSingle-blindTreatment

Summary

The purpose of this study is to compare the efficacy and safety of a new artificial tear formulation (011516X) with Systane® Ultra Multidose for 90 days in participants with Dry Eye Disease (DED).

Timeline

Start
2020-06-29
Primary completion
2021-06-15
Completion
2021-06-15

Drugs

EvaluationDrugModalityDoseRoute
Subject 011516X Unknown Topical
Comparator Systane Ultra Multidose Unknown Topical
Background Carboxymethylcellulose Other / unclassified Topical

Indications